The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Don't think most of us were laughing at any point, just investing our hard earned money in the businesses that we believe present the best opportunity based on our personal risk appetite and research.
Which continues regardless of other people's fun making and individual hopes.
Ok yes fair enough drifting, I understand now you were referencing only online reviews and thank you for sharing your experience, also really appreciate that you've acknowledged the efficacy of the study. I hope you can eventually find relief from the condition drifting.
What we do know drifting is that...
The AxisBiotix-Ps™ food supplement consumer study unveiled that participants who self-identified as having psoriasis experienced reduction in skin itchiness (76%), redness (75%), irritability (73%).
So that's a phenomenal percentage of millions of sufferers worldwide that this natural product can help.
If you've given it a good go, at least for a few months, then you are unfortunately in the circa 26%.
Please don't make false statements like ' it seems that many of the positive reviews come from people without psoriasis but with other skin problems' That's simply not true and I'm guessing you either missunderstood or have some reason to want to devalue the study results?
Everyone's aware the product isn't 100% effective, we accept it won't work for every single person sadly. The study results are still fantastic and with the efficacy shown can help millions of sufferers worldwide without the need for a prescription. That's phenomenal in my eyes.
Yes well done for staying strong Kev, it's one of the hardest parts of investing I think for many, making consistent rational decisions, sticking to your plan even in the face of extreme situations! Hopefully we're firmly on the way back up now. GLA
I think it was likely the short-term investors hoping it would quickly hit £1+ that were dismayed at the falling SP and got out. Anyone in long-term, who has diligently researched the business and has realistic timeframes on returns would have held, surely?
Thanka for clarifying John, yes I missunderstand, you weren't clear. It is about a delay that you think the podcast intimated. Respectfully disagree. You're making a massive assumption and have no evidence. DYOR carefully is my advice!
Thanks for highlighting this Mucksy.
John - yes I've listened to the podcast and I cannot remember anything about a delay associated with the 2022 roll out target. Can you tell me where it is?